Cargando…

Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease

Anesthesia for percutaneous transluminal angioplasty (PTA) involves a high-risk population having a broad spectrum of pain character and intensity. This study delved the anesthetic efficacy of dexmedetomidine versus midazolam, when used with remifentanil. Seventy patients scheduled for femoropoplite...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ji-Hyoung, Soh, Sarah, Kwak, Young-Lan, Kim, Bosung, Choi, Sohyun, Shim, Jae-Kwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518185/
https://www.ncbi.nlm.nih.gov/pubmed/30959941
http://dx.doi.org/10.3390/jcm8040472
_version_ 1783418408347369472
author Park, Ji-Hyoung
Soh, Sarah
Kwak, Young-Lan
Kim, Bosung
Choi, Sohyun
Shim, Jae-Kwang
author_facet Park, Ji-Hyoung
Soh, Sarah
Kwak, Young-Lan
Kim, Bosung
Choi, Sohyun
Shim, Jae-Kwang
author_sort Park, Ji-Hyoung
collection PubMed
description Anesthesia for percutaneous transluminal angioplasty (PTA) involves a high-risk population having a broad spectrum of pain character and intensity. This study delved the anesthetic efficacy of dexmedetomidine versus midazolam, when used with remifentanil. Seventy patients scheduled for femoropopliteal PTA were randomized into two groups receiving either intermittent midazolam boluses (0.03–0.05 mg/kg) (MR group) or dexmedetomidine 0.2–0.7 μg/kg/h after a loading dose of 1.0 μg/kg for 10 min (DR group), both with remifentanil. The primary endpoint was the patients’ satisfaction (1–5, 5; extremely satisfied). Secondary endpoints included postprocedural pain scores (0–10, 10; worst imaginable pain) and adverse events. The satisfaction level of patients was significantly greater in the DR group compared with the MR group (4.0 [3.0, 5.0] versus 4.0 [2.0, 5.0] p = 0.021). The number of patients having a postprocedural pain score of at least 3 was significantly greater in the MR group compared with the DR group (10 [29%] versus 2 [6%], p = 0.013). The number of patients with hypotensive episodes was higher in the DR group (5 [14.7%] versus 0, p = 0.025), which could all be restored with ephedrine. The use of dexmedetomidine in conjunction with remifentanil may be a safe option that provides excellent patient satisfaction while potentially attenuating postprocedural pain.
format Online
Article
Text
id pubmed-6518185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65181852019-05-31 Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease Park, Ji-Hyoung Soh, Sarah Kwak, Young-Lan Kim, Bosung Choi, Sohyun Shim, Jae-Kwang J Clin Med Article Anesthesia for percutaneous transluminal angioplasty (PTA) involves a high-risk population having a broad spectrum of pain character and intensity. This study delved the anesthetic efficacy of dexmedetomidine versus midazolam, when used with remifentanil. Seventy patients scheduled for femoropopliteal PTA were randomized into two groups receiving either intermittent midazolam boluses (0.03–0.05 mg/kg) (MR group) or dexmedetomidine 0.2–0.7 μg/kg/h after a loading dose of 1.0 μg/kg for 10 min (DR group), both with remifentanil. The primary endpoint was the patients’ satisfaction (1–5, 5; extremely satisfied). Secondary endpoints included postprocedural pain scores (0–10, 10; worst imaginable pain) and adverse events. The satisfaction level of patients was significantly greater in the DR group compared with the MR group (4.0 [3.0, 5.0] versus 4.0 [2.0, 5.0] p = 0.021). The number of patients having a postprocedural pain score of at least 3 was significantly greater in the MR group compared with the DR group (10 [29%] versus 2 [6%], p = 0.013). The number of patients with hypotensive episodes was higher in the DR group (5 [14.7%] versus 0, p = 0.025), which could all be restored with ephedrine. The use of dexmedetomidine in conjunction with remifentanil may be a safe option that provides excellent patient satisfaction while potentially attenuating postprocedural pain. MDPI 2019-04-06 /pmc/articles/PMC6518185/ /pubmed/30959941 http://dx.doi.org/10.3390/jcm8040472 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Park, Ji-Hyoung
Soh, Sarah
Kwak, Young-Lan
Kim, Bosung
Choi, Sohyun
Shim, Jae-Kwang
Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease
title Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease
title_full Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease
title_fullStr Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease
title_full_unstemmed Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease
title_short Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease
title_sort anesthetic efficacy of dexmedetomidine versus midazolam when combined with remifentanil for percutaneous transluminal angioplasty in patients with peripheral artery disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518185/
https://www.ncbi.nlm.nih.gov/pubmed/30959941
http://dx.doi.org/10.3390/jcm8040472
work_keys_str_mv AT parkjihyoung anestheticefficacyofdexmedetomidineversusmidazolamwhencombinedwithremifentanilforpercutaneoustransluminalangioplastyinpatientswithperipheralarterydisease
AT sohsarah anestheticefficacyofdexmedetomidineversusmidazolamwhencombinedwithremifentanilforpercutaneoustransluminalangioplastyinpatientswithperipheralarterydisease
AT kwakyounglan anestheticefficacyofdexmedetomidineversusmidazolamwhencombinedwithremifentanilforpercutaneoustransluminalangioplastyinpatientswithperipheralarterydisease
AT kimbosung anestheticefficacyofdexmedetomidineversusmidazolamwhencombinedwithremifentanilforpercutaneoustransluminalangioplastyinpatientswithperipheralarterydisease
AT choisohyun anestheticefficacyofdexmedetomidineversusmidazolamwhencombinedwithremifentanilforpercutaneoustransluminalangioplastyinpatientswithperipheralarterydisease
AT shimjaekwang anestheticefficacyofdexmedetomidineversusmidazolamwhencombinedwithremifentanilforpercutaneoustransluminalangioplastyinpatientswithperipheralarterydisease